Chloro-substituted dipicolinate vanadium complexes: Synthesis, solution, solid-state, and insulin-enhancing properties

Effect of the chloro-substitution on lowering diabetic hyperglycemia of vanadium complexes with their permeability and cytotoxicity

“…These results were similar to those of VdipiceCl complexes reported by Sakurai et al and Crans et al [23,28], suggesting that the chloro substituent increased the insulin-enhancing properties of the complex. By comparison, there is no simple and close structureeactivity relationships among these complexes, and the chloride substituent have potentially significant effects on the activity of a complex.…”

4-Fluoro-N'-(2-hydroxy-3-methoxybenzylidene) benzohydrazide and its Oxidovanadium(V) Complex: Syntheses, Crystal Structures and Insulin-enhancing Activity

“…Crystallographic data for the structural analysis has been deposited with the Cambridge Crystallographic Data Centre (CCDC-1477846 for H 2 …”

“…[1][2][3][4] Studies indicated that vanadium compounds improve not only hyperglycemia in human subjects and animal models of type I diabetes but also glucose homeostasis in type II diabetes .5,6 However, the inorganic vanadium salts are considered as less active and more toxic. In order to reduce the side effects of inorganic vanadium salts, vanadium complexes with various organic ligands have received particular attention and demonstrated to be effective.…”

Synthesis, characterization and urease inhibitory activity of oxovanadium(V) complexes with similar Schiff bases

“…During the search of literature, we found that the vanadium(IV) complexes also possess interesting urease inhibitory activities [16]. Vanadium complexes have been widely investigated in biological chemistry, especially for their insulinenhancing activities [17][18][19]. In this paper, a series of oxovanadium(V) complexes, [VO 2 L 1 ] (1), [VO 2 L 2 ] (2), [VO 2 L 3 ] (3), and 2[VO 2 L 4 ]•CH 3 OH (4) (HL 1 = 1-[(2-dimethylaminoethylimino)methyl]naphthalen-2-ol, HL 2 =1-[(2-diethylaminoethylimino)methyl]naphthalen-2-ol, HL 3 =1-[(2-piperidin-1-ylethylimino)methyl]naphthalen-2-ol, HL 4 = 1-[(2-morpholin-4-ylethylimino)methyl]naphthalen-2-ol; Scheme 1) were synthesized and structurally characterized.…”

“…The structure-activity relationship indicates that the shorter the terminal groups of the Schiff base ligands are, the stronger the urease inhibitory activities of the oxovanadium(V) complexes. Considering that the oxovanadium complexes have interesting biological activities and have been widely used in medicine [17][18][19]31,32], the complexes may be used in the treatment of infections caused by urease producing bacteria. …”